In this article, we discuss the Paul Marshall and Ian Wace’s top 5 stock picks. If you want to read our detailed analysis of Marshall and Wace’s history, investment philosophy, and hedge fund performance, go directly to Paul Marshall and Ian Wace’s 10 Stock Picks: Biogen Inc (BIIB) Apple Inc (AAPL) and More.
5. Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN)
Marshall and Wace’s Stake Value: $265,259,000
Percentage of Paul Marshall and Ian Wace’s 13F Portfolio: 1.19%
Number of Hedge Fund Holders: 27
Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) is a biopharmaceutical company that develops medicines for neurological illnesses and uncommon conditions. The company was established in 2013 and is placed fifth on the list of Paul Marshall and Ian Wace’s stock picks.
On September 13, Cantor Fitzgerald analyst Charles Duncan raised his price target on Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) to $165 from $151 and reiterated an “Overweight” rating on the shares. On August 9, Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) posted earnings for the second quarter of 2021. It reported earnings per share of -$2.62, missing the predictions by $0.38. Revenue over the period was $92.9 million, up 858.7% YoY, beating the estimates by $7.05 million.
Paul Marshall and Ian Wace’s Marshall Wace LLP currently owns 2.73 million shares of Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) worth $265.26 million. Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) occupies 1.19% of Marshall Wace LLP’s overall equity. In addition, there were 27 hedge funds in our database that held stakes in Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) in the second quarter 2021, compared to 33 funds in the previous quarter.
Baron Funds, in its first-quarter 2021 investor letter, mentioned Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN). Here is what the fund said:
“Biohaven Pharmaceutical Holding Company Ltd. is a biotechnology company dedicated to neurologic drug discovery. It launched its lead asset, migraine medication Nurtec, last year, and the company is transitioning towards profitability. Shares declined when Biohaven issued a secondary offering in March that took investors by surprise and seemed early in relation to an expected second indication for Nurtec in the prophylactic prevention of migraine, which expands its market. We exited our position.”
4. Bio-Rad Laboratories, Inc. (NYSE:BIO)
Marshall and Wace’s Stake Value: $280,330,000
Percentage of Paul Marshall and Ian Wace’s 13F Portfolio: 1.26%
Number of Hedge Fund Holders: 41
Bio-Rad Laboratories, Inc. (NYSE:BIO) is a life science research and clinical diagnostics company that develops, produces, and markets products. The company was founded in 1952 and is ranked fourth on the list of Paul Marshall and Ian Wace’s stock picks.
On July 29, Bio-Rad Laboratories, Inc. (NYSE:BIO) announced earnings for the second quarter of 2021. It posted earnings per share of $3.54, beating the estimates by $0.84. Revenue over the period was $715.9 million, up 33.3% YoY, surpassing the estimates by $73.29 million.
The hedge fund chaired by Paul Marshall and Ian Wace holds 435,099 shares of Bio-Rad Laboratories, Inc. (NYSE:BIO), worth $280.33 million. Marshall Wace LLP has trimmed its stake in the firm by 24% in the second quarter of 2021. As of the second quarter of 2021, 41 hedge funds have positions in Bio-Rad Laboratories, Inc. (NYSE:BIO), compared with 44 in the previous quarter.
3. Amazon.com, Inc. (NASDAQ:AMZN)
Marshall and Wace’s Stake Value: $280,360,000
Percentage of Paul Marshall and Ian Wace’s 13F Portfolio: 1.26%
Number of Hedge Fund Holders: 271
Amazon.com, Inc. (NASDAQ:AMZN) is an online retailer that sells consumer items and subscriptions. The company was founded in 1994 and stands third on the list of Paul Marshall and Ian Wace’s stock picks.
Marshall Wace LLP holds 81,496 shares in Amazon.com, Inc. (NASDAQ:AMZN), worth over $280.36 million, representing 1.26% of their investment portfolio. There were 271 hedge funds in our database that held stakes in Amazon.com, Inc. (NASDAQ:AMZN) in the second quarter of 2021, compared to 243 funds in the previous quarter.
L1 Capital, in its second-quarter 2021 investor letter, mentioned Amazon.com, Inc. (NASDAQ:AMZN). Here is what the fund said:
“Amazon flipped from being the largest detractor from portfolio performance in the March 2021 quarter, to one of the leading contributors in the June 2021 quarter. We took advantage of negative near-term sentiment in the March 2021 quarter to add to our Amazon investment. We continue to view Amazon as one of the best positioned businesses globally, with its share price still not reflecting fair value.”
2. Microsoft Corporation (NASDAQ:MSFT)
Marshall and Wace’s Stake Value: $286,045,000
Percentage of Paul Marshall and Ian Wace’s 13F Portfolio: 1.29%
Number of Hedge Fund Holders: 238
On September 14, Microsoft Corporation (NASDAQ:MSFT) announced a quarterly dividend of $0.62 per share, up $0.06, or 11%, from the previous quarter. On September 13, Infosys Limited (NYSE:INFY) and Microsoft Corporation (NASDAQ:MSFT) collaborated to accelerate Ausgrid’s cloud transformation journey. Together they will also establish Ausgrid as a digital utility.
The hedge fund chaired by Paul Marshall and Ian Wace holds 1.06 million shares in Microsoft Corporation (NASDAQ:MSFT) worth over $286.05 million. There were 238 hedge funds in our database that held stakes in Microsoft Corporation (NASDAQ:MSFT) in the second quarter of 2021, compared to 251 funds in the previous quarter.
Baron Opportunity Fund, in its second-quarter 2021 investor letter, highlighted a few stocks, and Microsoft Corporation (NASDAQ:MSFT) is one of them. Here is what the fund said:
“Shares of Microsoft Corporation, a cloud-software leader and provider of software productivity tools and infrastructure, rose during the quarter following a strong earnings report highlighting solid demand for its broad product stack and continued momentum migrating its business to the cloud. Microsoft was a top contributor in the period because it trades at reasonable free cash flow and earnings valuations, has cloud and digital transformation tailwinds at its back, reported a solid March quarter, and beat Street expectations by a wide margin. Microsoft’s results continued to be strong across the board, with Azure cloud computing revenues up 46% in constantcurrency (“cc”) terms and commercial cloud bookings growth of 38% cc, the best in years. Microsoft also reported robust profitability growth, with operating income expanding 31% and GAAP earnings up 45%. We believe the company is well positioned for continued solid growth and profitability through market share gains as more companies look to transform and digitize their businesses as they move operations to the cloud.”
1. Teleflex Incorporated (NYSE:TFX)
Marshall and Wace’s Stake Value: $368,740,000
Percentage of Paul Marshall and Ian Wace’s 13F Portfolio: 1.66%
Number of Hedge Fund Holders: 30
Teleflex Incorporated (NYSE:TFX) designs, develops, manufactures, and distributes single-use medical devices for routine diagnostic and therapeutic procedures in critical care and surgical settings. The company was founded in 1943 and is placed first on the list of Paul Marshall and Ian Wace’s stock picks. Teleflex Incorporated (NYSE:TFX) shares have returned 14.41% to investors over the course of the past 12 months.
On September 7, Raymond James analyst Jayson Bedford initiated coverage of Teleflex Incorporated (NYSE:TFX) with an “Outperform” rating and set a price target at $440. On July 29, Teleflex Incorporated (NYSE:TFX) declared a quarterly dividend of $0.34 per share, in line with the previous.
Paul Marshall and Ian Wace’s Marshall Wace LLP holds 917,743 shares in Teleflex Incorporated (NYSE:TFX), worth over $368.74 million, representing 1.66% of their portfolio. Alexander Becker’s Codex Capital is Teleflex Incorporated (NYSE:TFX) most significant stakeholder, with 11,900 shares worth $4.77 billion.
ClearBridge Investments, in its first-quarter 2021 investor letter, mentioned Teleflex Incorporated (NYSE: TFX). Here is what the fund said:
“Teleflex is a diversified medical device company with leading market share in several low-cost consumable niche categories, creating high-margin recurring revenue streams with steady growth and pricing. Its unique UroLift product has the potential to accelerate growth of the company with its strong positioning as the only minimally invasive product to treat BPH in the prostate gland with no side effects, a treatment area with a large total addressable market.”
You can also take a peek at Billionaire James Dinan’s Top 10 Stock Picks and Billionaire Ken Fisher’s Top 10 High Dividend Stock Picks
